You might also like
No business description found.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Timothy C. Wentworth ExecutiveBoard | Chief Executive Officer | Board of Trustees, University of Rochester; Director, Concordance Academy of Leadership; Executive Committee Member, Opera Theatre of St. Louis | Timothy C. Wentworth was appointed as CEO and a member of the Board of Directors on October 23, 2023. He has nearly three decades of healthcare leadership experience. | View Report → |
Beth Leonard Executive | Senior Vice President and Chief Corporate Affairs Officer | None | Beth Leonard joined WBA in June 2023 and oversees corporate affairs, including Government Relations, Public Affairs, and Corporate Communications. | |
Elizabeth Burger Executive | Executive Vice President and Chief Human Resources Officer | None | Elizabeth Burger joined WBA as CHRO in February 2024. She has over 25 years of business experience. | |
Lanesha Minnix Executive | Executive Vice President and Global Chief Legal Officer | None | Lanesha Minnix has been in her role since April 2024. She previously served as Executive Vice President, General Counsel, and Corporate Secretary for Ecolab Inc.. | |
Manmohan Mahajan Executive | Executive Vice President and Global Chief Financial Officer | None | Manmohan Mahajan joined WBA in 2016 and has held various financial leadership roles. He focuses on increasing cash flow and achieving cost savings. | |
Mary Langowski Executive | Executive Vice President and President of U.S. Healthcare | None | Mary Langowski leads WBA's U.S. Healthcare segment, focusing on expanding Walgreens' role in healthcare. She joined WBA in February 2024. | |
Neal Sample Executive | Executive Vice President and Chief Information Officer | None | Neal Sample joined WBA as CIO in October 2023, focusing on improving the digital experience for customers and patients. | |
Ornella Barra Executive | Chief Operating Officer, International | Director at Cencora | Ornella Barra oversees WBA's businesses outside the United States. She has been with WBA since its inception in December 2014. | |
Rick Gates Executive | Senior Vice President and Chief Pharmacy Officer | NACDS; Innovation Associates, Inc.; Pharmacy Quality Alliance | Rick Gates has been with Walgreens since 1995 and plays a critical role in advancing Walgreens' pharmacy and specialty pharmacy businesses. | |
Tracey Brown Executive | Executive Vice President and President of Walgreens Retail and Chief Customer Officer | None | Tracey Brown oversees Walgreens' retail business and consumer experience. She joined WBA in November 2021. | |
Bryan C. Hanson Board | Independent Director | Solventum Corporation | Bryan C. Hanson joined the WBA Board in October 2022. He has extensive experience in healthcare and technology. | |
Ginger L. Graham Board | Lead Independent Director | Board of Directors of VillageMD | Ginger L. Graham has been a member of the WBA Board since 2010 and was named Interim CEO in September 2023. | |
Inderpal S. Bhandari Board | Independent Director | The AES Corporation | Inderpal S. Bhandari was appointed to the WBA Board in September 2022. He brings expertise in technology and data strategy. | |
Janice M. Babiak Board | Independent Director | Bank of Montreal; VillageMD | Janice M. Babiak has been an independent director at WBA since April 2012. She is the Chair of the Audit Committee. | |
John A. Lederer Board | Independent Director | NextPoint Financial, Inc.; CEO and Executive Chairman of Staples, Inc.; Executive Chairman of Rona Canada | John A. Lederer has been an independent director at WBA since April 2015. He has extensive experience in retail and healthcare industries. | |
Nancy M. Schlichting Board | Independent Director | Director at Baxter International, Inc.; Director at Encompass Health Corporation; Board Member at Duke University and Duke University Health System | Nancy M. Schlichting has been an independent director at WBA since October 2006. She is the Chair of the Compensation and Leadership Performance Committee. | |
Robert L. Huffines Board | Independent Director | Nextech Invest; Eikon Therapeutics; Hastings Center for Biomedical Ethics | Robert L. Huffines joined the WBA Board in January 2024. He has over 30 years of experience in advising healthcare companies. | |
Stefano Pessina Board | Executive Chairman of the Board | Board memberships in several privately held companies | Stefano Pessina has been a director at WBA since April 2012 and has served as Executive Chairman since March 2021. He has significant experience in mergers and acquisitions, which has been critical to WBA's growth and transformation. | |
Thomas E. Polen Board | Independent Director | Chairman and CEO of Becton, Dickinson and Company; Board Member at AdvaMed, Hackensack Meridian Health Center for Discovery and Innovation | Thomas E. Polen was appointed to the WBA Board in July 2023. He has significant expertise in healthcare solutions and technologies. | |
Valerie B. Jarrett Board | Independent Director | CEO of The Barack Obama Foundation; Board Member at Ralph Lauren Corporation, Sweetgreen, Inc., Ariel Investments, LLC, Help at Home | Valerie B. Jarrett has been an independent director at WBA since October 2020. She is recognized for her expertise in governmental and public policy matters. | |
William H. Shrank Board | Independent Director | Venture Partner at Andreessen Horowitz; Board Member at WW International, Inc. | William H. Shrank was appointed to the WBA Board in September 2024. He brings a wealth of healthcare expertise and strategic insight. |
-
Given your plan to close approximately 1,200 stores over the next three years, how do you anticipate this will impact your market share and what specific strategies are in place to retain customers from these underperforming locations?
-
You mentioned the need to stabilize pharmacy margins and address reimbursement pressures; can you elaborate on the concrete steps you're taking to negotiate better terms with PBMs and how confident you are in achieving sustainable reimbursement rates?
-
With the reorientation to a retail pharmacy-led model and investments planned for higher-performing stores, how will you differentiate Walgreens from competitors who have already invested in similar capabilities, and what is your timeline for closing this competitive gap?
-
Considering the ongoing challenges with consumer price sensitivity and declining retail sales, especially in non-essential categories, what specific initiatives are you implementing to drive retail growth and improve gross margins without relying solely on cost-cutting measures?
-
Regarding your intention to monetize non-core assets like VillageMD to strengthen your balance sheet, how will this divestiture affect your long-term healthcare strategy, and what are the potential risks to your growth prospects in the U.S. Healthcare segment?
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Starling MSO Holdings, LLC | 2024 | The acquisition closed on March 3, 2023 with a total consideration of $284 million—comprising $222 million in cash and $62 million in VillageMD equity—and its purchase price allocation in fiscal 2024 recognized $103 million in goodwill and $128 million in intangible assets. |
Summit Health‑CityMD | 2023 | Completed on January 3, 2023, this acquisition involved an aggregate consideration of $7.0 billion (including $4.85 billion in cash, $2.05 billion in Preferred Units, and an additional $100 million deferred cash payment), repaid $1.9 billion in net debt, and is projected to deliver $150 million in pre-tax run‑rate synergies. |
CareCentrix | 2023 | Completed in two stages, with WBA acquiring the remaining 45% interest for $378 million on March 31, 2023 following an initial acquisition of 55% for $339 million in 2022, thereby consolidating CareCentrix into WBA’s U.S. Healthcare segment and strengthening its position in the post‑acute and home care management market. |
Shields Health Solutions | 2022 | WBA acquired the remaining 30% equity interest for approximately $1.37 billion in cash in 2022 (with the transaction expected to close by Q2 fiscal 2023), aiming to complete its full ownership of Shields to enhance its specialty pharmacy capabilities and expand its consumer‑centric healthcare strategy. |
Recent press releases and 8-K filings for WBA.
- The company disclosed on April 18, 2025 that it has entered into a settlement agreement with the DOJ and DEA to resolve litigation related to opioid dispensing rules and controlled substances matters.
- Under the terms, Walgreens Boots Alliance will pay $300 million plus interest over six years, with an immediate initial payment of $20 million due within 21 days.
- The agreement also provides for a potential additional $50 million contingency payment if free cash flow targets are met or if there is a sale, merger, or asset transfer during the settlement term.
- Loss per share narrowed to $3.30, compared to $6.85 in the same quarter last year, with significant non-cash impairment charges of $4.2 billion and after-tax gains of $1.0 billion impacting results.
- Adjusted EPS declined to $0.63 from $1.20 year-over-year, attributed primarily to lower U.S. retail sales and tax-effect adjustments.
- Sales increased by 4.1% year-over-year to $38.6 billion (up 4.7% on a constant currency basis), driven by strength in U.S. Retail Pharmacy and International segments.
- The company has withdrawn fiscal 2025 guidance in light of the pending transaction with affiliates of Sycamore Partners.
- Merger Filing: Walgreens Boots Alliance, Inc. has filed an 8-K disclosing its planned merger with Blazing Star Parent, LLC and affiliated entities, with key transaction events dated March 6, 2025.
- Transaction Process: The filing details the Agreement and Plan of Merger, including provisions for stockholder meetings, proxy statement preparation, and related compliance measures to ensure proper execution of the merger.